Background Progressive supranuclear palsy (PSP) is a rare neurodegenerative condition characterised by a range of motor and cognitive symptoms. Very little is known about the longitudinal change in these symptoms over time. Moreover, the effectiveness of clinical scales to detect early changes in PSP is still a matter of debate. Objective We aimed to determine longitudinal changes in PSP features using multiple closely spaced follow-up time points over a period of 2 years. Methods 28 healthy control and 28 PSP participants, with average time since onset of symptoms of 1.9 years, were prospectively studied every 3 months for up to 24 months. Changes from baseline scores were calculated at each follow-up time point using multiple clinical s...
Introduction: Prediagnostic features of Parkinson’s Disease are well described but prediagnostic Pro...
Objective Multiple System Atrophy (MSA) and progressive supranuclear palsy (PSP) are rapidly progre...
BackgroundThere is currently no undisputed, validated, clinically meaningful measure for deficits in...
We studied the annual change in measures of motor, oculomotor and cognitive function in progressive ...
Objective: We studied the annual change in measures of motor, oculomotor and cognitive function in p...
Objective: This study investigated neuropsychological tests most sensitive in differentiating progre...
Objective: This study investigated neuropsychological tests most sensitive in differentiating progre...
Objective: Progressive supranuclear palsy (PSP) is associated with a variety of cognitive deficits, ...
Cognitive impairment is frequent in progressive supranuclear palsy (PSP) and less common in multiple...
INTRODUCTION: Prediagnostic features of Parkinson's Disease are well described but prediagnostic Pro...
INTRODUCTION: Prediagnostic features of Parkinson's Disease are well described but prediagnostic Pro...
BackgroundDespite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it ...
Cognitive impairment is frequent in progressive supranuclear palsy (PSP) and less common in multiple...
Background: There is currently no undisputed, validated, clinically meaningful measure for deficits ...
Describe PSP Study Group, the ProPSP Study Group, and the Movement Disorder Society–Endorsed PSP Stu...
Introduction: Prediagnostic features of Parkinson’s Disease are well described but prediagnostic Pro...
Objective Multiple System Atrophy (MSA) and progressive supranuclear palsy (PSP) are rapidly progre...
BackgroundThere is currently no undisputed, validated, clinically meaningful measure for deficits in...
We studied the annual change in measures of motor, oculomotor and cognitive function in progressive ...
Objective: We studied the annual change in measures of motor, oculomotor and cognitive function in p...
Objective: This study investigated neuropsychological tests most sensitive in differentiating progre...
Objective: This study investigated neuropsychological tests most sensitive in differentiating progre...
Objective: Progressive supranuclear palsy (PSP) is associated with a variety of cognitive deficits, ...
Cognitive impairment is frequent in progressive supranuclear palsy (PSP) and less common in multiple...
INTRODUCTION: Prediagnostic features of Parkinson's Disease are well described but prediagnostic Pro...
INTRODUCTION: Prediagnostic features of Parkinson's Disease are well described but prediagnostic Pro...
BackgroundDespite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it ...
Cognitive impairment is frequent in progressive supranuclear palsy (PSP) and less common in multiple...
Background: There is currently no undisputed, validated, clinically meaningful measure for deficits ...
Describe PSP Study Group, the ProPSP Study Group, and the Movement Disorder Society–Endorsed PSP Stu...
Introduction: Prediagnostic features of Parkinson’s Disease are well described but prediagnostic Pro...
Objective Multiple System Atrophy (MSA) and progressive supranuclear palsy (PSP) are rapidly progre...
BackgroundThere is currently no undisputed, validated, clinically meaningful measure for deficits in...